January 8, 2025: MaaT Pharma touts ‘unprecedented’ Phase 3 efficacy of graft-versus-host disease treatment - Endpoints News - MaaT Pharma

To see the article, click here!

Previous PostJanuary 9, 2025: ARES Trial of MaaT013 in GI-aGVHD Meets Primary End Point of GI-ORR - OncLive
Next PostJanuary 8, 2025: Drug From Bowel Bacteria Helps Blood Cancer Patients Facing Deadly Complication - Bloomberg

© 2025 MaaT Pharma. MaaT Pharma’s mission is to restore microbiome function to treat life-threatening diseases

MaaT Pharma dans les médias MaaT Pharma in the News Devenez membre du club Become a member of the club